An2 Therapeutics extends funding for tuberculosis research collaboration with GSK
The Gates Foundation funding supports advancement of boron-based LeuRS inhibitors for TB treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Gates Foundation extends funding for AN2 Therapeutics' TB research collaboration with GSK
Funding supports development of boron-based leucyl-tRNA synthetase inhibitors as potential tuberculosis treatments.
AN2 Therapeutics extends Gates Foundation funding for TB research with GSK
The company said the Gates Foundation awarded an extension of funding to support its ongoing tuberculosis research collaboration with GSK. The work focuses on boron-based leucyl-tRNA synthetase inhibitors.